MCID: ISL001
MIFTS: 53

Islet Cell Tumor

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Islet Cell Tumor

MalaCards integrated aliases for Islet Cell Tumor:

Name: Islet Cell Tumor 38 12 55 15 73
Well Differentiated Pancreatic Endocrine Tumor 73
Malignant Neoplasm of Endocrine Pancreas 73
Malignant Tumor of Endocrine Pancreas 12
Malignant Pancreatic Endocrine Tumor 12
Pancreatic Endocrine Carcinoma 73
Pancreatic Endocrine Neoplasm 12
Endocrine Pancreas Cancer 12
Carcinoma Islet Cell 55
Islet Cell Neoplasm 12
Adenoma, Islet Cell 44
Islet Cell Tumour 12

Classifications:



Summaries for Islet Cell Tumor

Disease Ontology : 12 A pancreatic cancer that is located in the pancreatic islet cells.

MalaCards based summary : Islet Cell Tumor, also known as well differentiated pancreatic endocrine tumor, is related to vipoma and insulinoma. An important gene associated with Islet Cell Tumor is SST (Somatostatin), and among its related pathways/superpathways are Signaling by GPCR and G alpha (s) signalling events. The drugs Miconazole and Sunitinib have been mentioned in the context of this disorder. Affiliated tissues include the pancreatic islet cells, pancreas and pancreatic islet, and related phenotypes are cardiovascular system and endocrine/exocrine gland

Related Diseases for Islet Cell Tumor

Diseases related to Islet Cell Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 162)
# Related Disease Score Top Affiliating Genes
1 vipoma 31.2 CHGA GAST SST VIP
2 insulinoma 30.9 CHGA INS MEN1 SST
3 duodenitis 30.7 GAST INS
4 somatostatinoma 30.4 CALCA CHGA INS SST VIP
5 glucagonoma 29.9 CHGA SST VIP
6 duodenal ulcer 29.8 GAST INS SST
7 peptic ulcer disease 29.6 GAST MEN1
8 neuroendocrine tumor 29.4 CALCA CHGA GAST MEN1 SST
9 gastrointestinal stromal tumor 29.3 CHGA IGF2 MEN1
10 zollinger-ellison syndrome 29.1 CHGA GAST MEN1 SST
11 multiple endocrine neoplasia 29.1 CALCA CHGA MEN1
12 acromegaly 28.7 IGF2 INS MEN1 SST
13 carcinoid syndrome 28.1 CALCA CHGA MEN1 SST
14 pheochromocytoma 27.6 CALCA CHGA MEN1 SST VIP
15 multiple endocrine neoplasia, type i 27.4 CHGA GAST INS MEN1 SST VIP
16 hyperparathyroidism 27.1 CALCA CHGA GAST MEN1 PTHLH
17 gastrinoma 26.8 CHGA GAST INS MEN1 SST VIP
18 pheochromocytoma--islet cell tumor syndrome 12.3
19 pancreatic neuroendocrine tumor 11.8
20 mahvash disease 11.2
21 pancreatic endocrine carcinoma 11.0
22 pancreatitis 10.7
23 pylorospasm 10.7 GAST SST
24 postcholecystectomy syndrome 10.7 GAST SST
25 adenoma of the pancreas 10.7 CHGA SST
26 gastrointestinal neuroendocrine tumor 10.7 CHGA SST
27 autoimmune atrophic gastritis 10.7 CHGA GAST
28 duodenogastric reflux 10.7 GAST SST
29 pituitary carcinoma 10.7 CHGA SST
30 retinitis pigmentosa 40 10.7 GAST SST
31 pernicious anemia 10.6 GAST SST
32 goblet cell carcinoid 10.6 CHGA GAST
33 pancreatoblastoma 10.6 CHGA SST
34 non-functioning pancreatic endocrine tumor 10.6 CHGA GAST
35 postural hypotension 10.6 INS SST
36 hypoglycemia 10.6
37 hyperpituitarism 10.5 INS SST
38 dumping syndrome 10.5 INS SST
39 spinal meningioma 10.5 CHGA IGF2
40 type 1 diabetes mellitus 2 10.5 IGF2 INS
41 hypoglycemic coma 10.5 IGF2 INS
42 spinal canal and spinal cord meningioma 10.5 CHGA IGF2
43 phaeochromocytoma 10.5 CHGA SST
44 sclerosing hepatic carcinoma 10.5 CHGA PTHLH
45 secretory diarrhea 10.4 SST VIP
46 cryptosporidiosis 10.4 SST VIP
47 liver sarcoma 10.4 CHGA PTHLH
48 pituitary-dependent cushing's disease 10.4 INS SST
49 granulosa cell tumor of the ovary 10.4 CHGA INS
50 prolactin producing pituitary tumor 10.4 CALCA SST

Graphical network of the top 20 diseases related to Islet Cell Tumor:



Diseases related to Islet Cell Tumor

Symptoms & Phenotypes for Islet Cell Tumor

MGI Mouse Phenotypes related to Islet Cell Tumor:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.88 MEN1 CHGA PTHLH IGF2 VIP INS
2 endocrine/exocrine gland MP:0005379 9.87 PTHLH GAST IGF2 VIP INS MEN1
3 homeostasis/metabolism MP:0005376 9.86 PTHLH GAST SST IGF2 VIP INS
4 digestive/alimentary MP:0005381 9.85 PTHLH GAST SST IGF2 INS MEN1
5 immune system MP:0005387 9.7 PTHLH GAST SST IGF2 VIP INS
6 mortality/aging MP:0010768 9.56 CHGA PTHLH GAST SST IGF2 VIP
7 reproductive system MP:0005389 9.1 CHGA PTHLH IGF2 VIP INS MEN1

Drugs & Therapeutics for Islet Cell Tumor

Drugs for Islet Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 159)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
2
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 341031-54-7, 557795-19-4 5329102
3
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
4
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
5
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
6
Pancrelipase Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 53608-75-6
7 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
8 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
9 Hormones Phase 4,Phase 3,Phase 2,Phase 1
10 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
12 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Hypoglycemic Agents Phase 4,Phase 2,Phase 1
14 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
16 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
18 pancreatin Phase 4,Phase 2,Phase 1,Not Applicable
19 insulin Phase 4,Not Applicable
20 Insulin, Globin Zinc Phase 4,Not Applicable
21 Fluorodeoxyglucose F18 Phase 4,Phase 2
22
Oxaliplatin Approved, Investigational Phase 2, Phase 3 61825-94-3 5310940 9887054 43805 6857599
23
Fluorouracil Approved Phase 2, Phase 3,Phase 3 51-21-8 3385
24
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
25
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2
26 lanreotide Approved Phase 3,Phase 2 108736-35-2
27
Streptozocin Approved, Investigational Phase 3,Phase 2 18883-66-4 29327
28
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
29
leucovorin Approved, Nutraceutical Phase 2, Phase 3,Phase 3 58-05-9 143 6006
30
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 1 59-30-3 6037
31 Pancreatic Polypeptide Investigational Phase 2, Phase 3,Phase 1,Not Applicable 59763-91-6
32 Antimetabolites Phase 2, Phase 3,Phase 3,Phase 1
33 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 3,Phase 1
34 Angiopeptin Phase 3,Phase 2
35 Pharmaceutical Solutions Phase 3,Phase 2
36 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
37 Dihydroxyphenylalanine Phase 3
38 Dopamine Agents Phase 3
39 Folate Nutraceutical Phase 2, Phase 3,Phase 1
40 Vitamin B9 Nutraceutical Phase 2, Phase 3,Phase 1
41
Metformin Approved Phase 2 657-24-9 14219 4091
42
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
43
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 383414 6400441
44
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
45
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
46
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
47
Doxorubicin Approved, Investigational Phase 2,Not Applicable 23214-92-8 31703
48
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
49
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
50
Omeprazole Approved, Investigational, Vet_approved Phase 2 73590-58-6 4594

Interventional clinical trials:

(show top 50) (show all 143)
# Name Status NCT ID Phase Drugs
1 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Unknown status NCT02759718 Phase 4
2 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4 everolimus
3 Nonfunctional Pancreatic NET and PET Imaging Recruiting NCT02621541 Phase 4
4 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525550 Phase 4 sunitinib
5 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4 Pasireotide;Diazoxide
6 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
7 Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour Completed NCT00842348 Phase 3 lanreotide (Autogel formulation)
8 Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours Completed NCT00353496 Phase 3 lanreotide (Autogel formulation);Placebo
9 Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors Completed NCT00510068 Phase 3 Everolimus;Everolimus Placebo
10 A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET) Recruiting NCT02288377 Phase 2, Phase 3 lanreotide;Placebo
11 Phase III Study of Sulfatinib in Treating Advanced Pancreatic Neuroendocrine Tumors Recruiting NCT02589821 Phase 3 Sulfatinib
12 Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced pNET Recruiting NCT02246127 Phase 3 Drug: Everolimus;STZ-5FU
13 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety Recruiting NCT03042416 Phase 3 18F-DOPA
14 Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment Not yet recruiting NCT02705651 Phase 3 Somatostatin-Analog
15 Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery Not yet recruiting NCT03375320 Phase 3 Cabozantinib S-malate
16 A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors Terminated NCT00428597 Phase 3 sunitinib malate;Placebo
17 Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs Unknown status NCT02294006 Phase 2 Everolimus plus Octreotide LAR plus Metformin
18 Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors Unknown status NCT01803503 Phase 2 Docetaxel;Sunitinib
19 Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer Unknown status NCT02188550 Phase 2 everolimus and letrozole
20 Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors Unknown status NCT02455596 Phase 2 Recombinant anti-tumor and anti-virus protein for injection (Novaferon)
21 BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. Completed NCT01658436 Phase 2 BEZ235 (Stage 1)
22 Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor Completed NCT01845675 Phase 2 temozolomide or dacarbazine-based chemotherapy, endostatin
23 68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours Completed NCT01673906 Phase 2 Diagnostic work up
24 AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Completed NCT01024387 Phase 2 AMG 479
25 Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Completed NCT01121562 Phase 2 Sunitinib
26 A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) Completed NCT02806648 Phase 2 Palbociclib
27 Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery Completed NCT02101918 Phase 2
28 Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas Completed NCT00001165 Phase 2 combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
29 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
30 Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer Completed NCT00001228 Phase 2 Interferon
31 Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET Completed NCT02231762 Phase 2 Lanreotide Autogel 120 mg;Temozolomide (TMZ)
32 Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy Completed NCT00363051 Phase 2 Everolimus 10 mg;Octreotide Depot
33 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
34 Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization Completed NCT00434109 Phase 2 Sunitinib malate
35 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
36 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET Completed NCT02162446 Phase 1, Phase 2 68Ga-OPS202
37 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
38 Pazopanib as Single Agent in Advanced NETs Completed NCT01280201 Phase 2 Pazopanib
39 The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid Completed NCT00001191 Phase 2 Pantoprazole;Omeprazole
40 Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET) Completed NCT00610129 Phase 2 MK-0646
41 KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors Completed NCT02250885 Phase 2 Selinexor
42 A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers Completed NCT02132468 Phase 2 fosbretabulin tromethamine
43 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
44 Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases Completed NCT00019786 Phase 2 isolated perfusion;melphalan
45 68Ga-DOTATATE PET Scan in Neuroendocrine Cancer Completed NCT01396382 Phase 2
46 A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor Recruiting NCT03204019 Phase 2 Tegafur and Temozolomide;Tegafur and Temozolomide combined with Thalidomide
47 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors Recruiting NCT02736448 Phase 2 Capecitabine;Lu-PRRT;SS-LAR
48 Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib Recruiting NCT02713763 Phase 2 Sunitinib
49 Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery Recruiting NCT02893930 Phase 2 Sapanisertib
50 Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery Recruiting NCT01465659 Phase 1, Phase 2 temozolomide;pazopanib hydrochloride

Search NIH Clinical Center for Islet Cell Tumor

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: adenoma, islet cell

Genetic Tests for Islet Cell Tumor

Anatomical Context for Islet Cell Tumor

The Foundational Model of Anatomy Ontology organs/tissues related to Islet Cell Tumor:

19
The Pancreatic Islet Cells

MalaCards organs/tissues related to Islet Cell Tumor:

41
Pancreas, Pancreatic Islet, Liver, Lung, Endothelial, Lymph Node, Bone

Publications for Islet Cell Tumor

Articles related to Islet Cell Tumor:

(show top 50) (show all 353)
# Title Authors Year
1
Late Onset of Non-islet Cell Tumor Hypoglycemia Managed via Multidisciplinary Treatment in a Patient with a Solitary Fibrous Tumor. ( 29526941 )
2018
2
Characterization of pancreatic islet cell tumors and renal tumors induced by a combined treatment of streptozotocin and nicotinamide in male SD rats. ( 28390812 )
2017
3
Non-Islet Cell Tumor Hypoglycemia: A Rare Cause of Hypoglycemia in Pulmonary Sarcomatoid Cancer. ( 29492361 )
2017
4
A Case of Non-Islet Cell Tumor Hypoglycemia (NICTH) Associated with Gastrointestinal Stromal Tumor (GIST). ( 28900071 )
2017
5
Levels of glucose-regulatory hormones in patients with non-islet cell tumor hypoglycemia: including a review of the literature. ( 28529277 )
2017
6
Non-islet cell tumor hypoglycemia caused by a big insulin-like growth factor II- producing hepatocellular carcinoma:an autopsy case report. ( 27916774 )
2016
7
Non-islet cell tumor hypoglycemia caused by intrathoracic solitary fibrous tumor: a case report. ( 27061182 )
2016
8
Fatal hepatitis B reactivation in a patient with islet cell tumor on octreotide and sirolimus. ( 26487953 )
2015
9
Non-Islet Cell Tumor Hypoglycemia Is Caused by Big IGF-II in a Patient with a Carcinosarcoma of the Uterus. ( 26666605 )
2015
10
The Transformation of a Nonfunctioning Islet Cell Tumor of the Pancreas into a Proinsulinoma under Conditions of Lung Metastasis. ( 25832942 )
2015
11
Multiple hepatocellular adenomas presenting in a male 8 years post-pancreaticoduodenectomy for islet cell tumor of the pancreas. ( 25810673 )
2015
12
Nonfunctional islet cell tumor of the pancreas in a patient with tuberous sclerosis: a case report with literature review. ( 24678435 )
2014
13
Characterization of a pancreatic islet cell tumor in a polar bear (Ursus maritimus). ( 25273481 )
2014
14
A 94-year-old man with recurrent hypoglycemia caused by non-islet cell tumor hypoglycemia (NICTH). ( 25780362 )
2014
15
Bioactive insulin-like growth factors as a possible molecular target for non-islet cell tumor hypoglycemia. ( 25535894 )
2014
16
Gastric neuroendocrine carcinoma with non-islet cell tumor hypoglycemia associated with enhanced production of insulin-like growth factor II. ( 23545670 )
2013
17
Management of Non-Islet-Cell Tumor Hypoglycemia: A Clinical Review. ( 24423303 )
2013
18
Nesidioblastosis and Pancreatic Non-functioning Islet Cell Tumor in an Adult with Type 2 Diabetes Mellitus. ( 24255640 )
2013
19
Non-islet cell tumor-induced hypoglycemia: a report of five cases and brief review of the literature. ( 24616774 )
2013
20
Metastatic Insulinoma Following Resection of Nonsecreting Pancreatic Islet Cell Tumor: A Case Report and Review of the Literature. ( 26425568 )
2013
21
Surgical treatment of pancreatic islet cell tumor: report of 44 cases. ( 24719954 )
2013
22
Non-Islet Cell Tumor-Induced Hypoglycemia Associated with Macronodular Pulmonary Metastases from Poorly Differentiated Thyroid Carcinoma. ( 23697382 )
2013
23
GPR119 expression in normal human tissues and islet cell tumors: evidence for its islet-gastrointestinal distribution, expression in pancreatic beta and alpha cells, and involvement in islet function. ( 22883930 )
2013
24
Non-islet cell tumor hypoglycemia associated with recurrent carcinosarcoma of the ovary. ( 23512392 )
2013
25
Sorafenib inhibits tumor growth and improves survival in a transgenic mouse model of pancreatic islet cell tumors. ( 23346016 )
2012
26
Recurrent solitary fibrous tumor of the pleura with malignant transformation and non-islet cell tumor-induced hypoglycemia due to paraneoplastic overexpression and secretion of high-molecular-weight insulin-like growth Factor II. ( 23207122 )
2012
27
Gastrointestinal stromal tumor of the pelvic soft tissue presenting with symptomatic hypoglycemia: A case report and brief review of current literature of non-islet cell tumor-induced hypoglycemia. ( 24371628 )
2012
28
Severe hypoglycemia with "Big"-IGF-2 oversecretion by a giant phyllode tumor of the breast: a rare case of non-islet cell tumor-induced hypoglycemia (NICTH). ( 22867750 )
2012
29
Non-islet cell tumor hypoglycemia at the second recurrence of malignant solitary fibrous tumor in the retroperitoneum and pelvis: a case report. ( 22949904 )
2012
30
Diabetic ketoacidosis with concurrent pancreatitis, pancreatic I^ islet cell tumor, and adrenal disease in an obese ferret (Mustela putorius furo). ( 21838985 )
2011
31
Pancreatic and peri-pancreatic lesions mimic pancreatic islet cell tumor in multidetector computed tomography. ( 21740785 )
2011
32
Retrospective Review of Cross Sectional Imaging Findings of Pancreatic Non-functional Islet Cell Tumor (NFICT) and its Hepatic Metastases. ( 22043378 )
2011
33
Non-islet cell tumor hypoglycemia associated with uterine leiomyomata. ( 21550955 )
2011
34
Hepatic abscess after yttrium-90 radioembolization for islet-cell tumor hepatic metastasis. ( 19688373 )
2010
35
A case of gastric cancer with non-islet cell tumor hypoglycemia detected by insulin-like growth factor II. ( 20618739 )
2010
36
Metastatic pancreatic polypeptide-secreting islet cell tumor in a dog. ( 20698942 )
2010
37
Systematic comparison of sporadic and syndromic pancreatic islet cell tumors. ( 20660572 )
2010
38
Diffusion weighted MR imaging of pancreatic islet cell tumors. ( 19264435 )
2010
39
Non-islet cell tumor hypoglycemia. ( 19345293 )
2009
40
Insulinoma with six islet cell tumors associated with severe hypoglycemia. ( 19525595 )
2009
41
Successful control of intractable hypoglycemia using rapamycin in an 86-year-old man with a pancreatic insulin-secreting islet cell tumor and metastases. ( 19567519 )
2009
42
Pancreatic islet cell tumor secreting insulin-like growth factor type-II in a dog. ( 19780935 )
2009
43
Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, alpha cell hyperplasia, and islet cell tumor. ( 19657311 )
2009
44
Hypoglycemia associated with the production of insulin-like growth factor II in a pancreatic islet cell tumor: a case report. ( 18490836 )
2008
45
Islet cell tumor of the pancreas: increasing diagnosis after instituting ultrasonography-guided fine needle aspiration. ( 18323274 )
2008
46
Spectrum of functioning islet cell tumor on multislice computed tomography: experience on 70 patients. ( 18437902 )
2008
47
Successful treatment of non-islet cell tumor hypoglycemia in hepatocellular carcinoma with doxorubicin. ( 18278497 )
2008
48
Spontaneous pancreatic islet cell tumor in a black and white colobus monkey (Colobus guereza kikuyuensis). ( 18269522 )
2008
49
Nesidioblastosis and hyperplasia of alpha cells, microglucagonoma, and nonfunctioning islet cell tumor of the pancreas: review of the literature. ( 18437091 )
2008
50
Non-islet-cell tumor hypoglycemia and lactic acidosis in a child with congenital HIV and Burkitt's lymphoma. ( 18825882 )
2008

Variations for Islet Cell Tumor

Expression for Islet Cell Tumor

Search GEO for disease gene expression data for Islet Cell Tumor.

Pathways for Islet Cell Tumor

Pathways related to Islet Cell Tumor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.45 CALCA GAST IGF2 INS MEN1 PTHLH
2 11.3 CALCA PTHLH VIP
3 10.98 IGF2 INS
4 9.47 GAST VIP

GO Terms for Islet Cell Tumor

Cellular components related to Islet Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 CALCA CHGA GAST IGF2 INS PTHLH
2 extracellular region GO:0005576 9.23 CALCA CHGA GAST IGF2 INS PTHLH

Biological processes related to Islet Cell Tumor according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.8 IGF2 INS PTHLH VIP
2 regulation of gene expression GO:0010468 9.71 IGF2 INS PTHLH
3 G-protein coupled receptor signaling pathway GO:0007186 9.63 CALCA GAST INS PTHLH SST VIP
4 cell-cell signaling GO:0007267 9.62 CALCA INS PTHLH SST
5 regulation of protein localization GO:0032880 9.56 INS VIP
6 response to heat GO:0009408 9.55 CALCA SST
7 positive regulation of mitotic nuclear division GO:0045840 9.52 IGF2 INS
8 positive regulation of blood vessel diameter GO:0097755 9.51 CALCA INS
9 osteoblast development GO:0002076 9.48 MEN1 PTHLH
10 positive regulation of insulin receptor signaling pathway GO:0046628 9.46 IGF2 INS
11 positive regulation of glycogen biosynthetic process GO:0045725 9.43 IGF2 INS
12 adenylate cyclase-activating G-protein coupled receptor signaling pathway GO:0007189 9.43 CALCA PTHLH VIP
13 positive regulation of cAMP metabolic process GO:0030816 9.4 CALCA CHGA
14 negative regulation of blood vessel diameter GO:0097756 9.37 CHGA INS
15 cellular protein metabolic process GO:0044267 9.26 CALCA IGF2 INS MEN1
16 regulation of signaling receptor activity GO:0010469 9.17 CALCA GAST IGF2 INS PTHLH SST

Molecular functions related to Islet Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin receptor binding GO:0005158 9.26 IGF2 INS
2 hormone activity GO:0005179 9.17 CALCA GAST IGF2 INS PTHLH SST
3 insulin-like growth factor receptor binding GO:0005159 9.16 IGF2 INS
4 receptor activator activity GO:0030546 8.96 IGF2 INS

Sources for Islet Cell Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....